2. Protein Tyrosine Kinase/RTK
  3. c-Met/HGFR
  4. Rilotumumab

Rilotumumab  (Synonyms: AMG 102)

Cat. No.: HY-P99217 Purity: 99.10%
COA
SDS
Technical Support

Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CAS No. : 872514-65-3

사이즈 가격 재고 수량
1 mg 해외재고보유
5 mg 해외재고보유
10 mg 해외재고보유
50 mg   견적 받기  
100 mg   견적 받기  

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

Rilotumumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • 순도&문서

  • References

  • 고객리뷰

제품 설명

Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research[1][2].

Isotype

Human IgG2 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

HGF/SF
In Vitro

Rilotumumab (10 μg/mL; overnight) shows the decrease of MET phosphorylation at Y1234 and Y1235, and an increase in total MET[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Rilotumumab Related Antibodies

Western Blot Analysis[2]

Cell Line: U87MG.vIII cells
Concentration: 10 μg/mL
Incubation Time: Overnight
Result: Showed MET phosphorylation at tyrosine residue 1234 (Y1234) and Y1235 ~50% lower in U87MG.vIII cells than in untreated cells.
Showed an increase in total MET compared with untreated cells.
In Vivo

Rilotumumab (intraperitoneal injection; 1.5 mg/kg; once two days; 11 d) treatment inhibits glioma cell growth in vivo[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: 6-8-week-old BALB/c nu/nu female mice subcutaneous injected with U87MG.vIII cells[2]
Dosage: 1.5 mg/kg
Administration: Intraperitoneal injection; 1.5 mg/kg; once two days; 11 days
Result: Reduced U87MG.vIII xenograft growth (P=0.0002) compared with vehicle-treated xenografts (P=0.0001).
Clinical Trial
Gene ID

3082  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
분자량

145.2 kDa

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Rilotumumab]
선적

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
보관

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG2 kappa
Biological Activity
  • Immobilized Human HGF Protein (C-6His) can bind Rilotumumab. The EC50 for this effect is 13.45 ng/mL.
순도&문서
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Rilotumumab Related Classifications

  • 몰농도 계산기

  • 농도 희석 계산기

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Rilotumumab872514-65-3AMG 102AMG102AMG-102c-Met/HGFRhepatocyte growth factorcastration-resistant prostate cancerCRPCsolid tumorU87MG.vIII cellInhibitorinhibitorinhibit

최근 본 상품:

온라인 문의

Your information is safe with us. * Required Fields.

상품명

  

Requested Quantity *

고객명 *

 

호칭

메일주소 *

 

전화번호 *

Department

 

회사명 *

City

도

Country or Region *

      

비고

대량구매 문의

Inquiry Information

상품명:
Rilotumumab
Cat. No.:
HY-P99217
수량:
MCE Japan Authorized Agent:

고객리뷰

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

상품명

  

Lot #

고객명 *

 

메일주소 *

전화번호

 

Department *

회사명 *

 

Country or Region *

비고

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.